Biocon Ltd. expects its biologics and small molecules businesses to continue its growth momentum in 2019-20, Chairperson and Managing Director Kiran Mazumdar Shaw said on Friday.
The company is seeing a good visibility in terms of order book and projects on hand, she told BloombergQuint in an interview. “Overall, we're going to have a very strong FY20.”
The biologics segment's revenue jumped 96 percent over last year to Rs 490 crore in the June quarter, the Bengaluru-based biotechnology firm said in an exchange filing. Its small molecule division's revenue grew 20 percent over the same period. Revenue of the company's branded formulations arm fell 9 percent year-on-year to Rs 133 crore.
Biocon Q1 Results 2019-20: Key Highlights (YoY)
- Revenue rose 30.4 percent to Rs 1,465.9 crore.
- Net profit increased 72.3 percent to Rs 206.3 crore.
- Ebitda rose 84 percent to Rs 437.5 crore.
- Margin stood at 29.8 percent versus 21.2 percent.
Watch the full interaction here:
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
